1.Medication Compliance Investigation and Pharmaceutical Care for 50 Cases of Hypertension
Jianjun ZHOU ; Guojiang PENG ; Yi CAO ; Shiyun WANG ; Xiaojin HUANG ; Pingmei DENG
China Pharmacist 2017;20(8):1414-1416
Objective: To understand the medication compliance of inpatients with essential hypertension, analyze the influencing factors in medication compliance of the patients and perform the targeted medication education and pharmaceutical care.Methods: Medication education and guide were conducted in 50 cases of patients with essential hypertension based on the main contents in guidelines for prevention of hypertension.Every patient completed regular follow-ups in two months after being recruited.The relevant information about the treatment and medication were collected and analyzed.Results: Through the medication education and pharmaceutical care, the patients had a better understanding on the relevant knowledge of hypertension, rational drug use and treatment.Among the 50 patients, the percentage of completely following the doctor's advice on the hypertension medication was 86%, that of quitting smoking and limiting alcohol was 82%, and that of optimized life way was 78%, and totally 82% of the patients effectively controlled blood pressure or improved markedly when compared with the situation on admission.Conclusion: Medication education and pharmaceutical care conducted by clinical pharmacists is very important for the patients with high blood pressure.It can help patients build a good lifestyle or improve the quality of life by improving the medication compliance of patients, alleviating complications and reducing adverse drug reactions.
2.Progress of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment
Pingmei HUANG ; Xiaolei HU ; Changsheng YE
Chinese Journal of Clinical Oncology 2019;46(16):865-868
s Triple-negative breast cancer (TNBC), a heterogeneous tumor that lacks the expression of estrogen receptor (ER), proges-terone receptor (PR), and human epidermal growth factor receptor 2 (HER2), is more aggressive and tends to recur or metastasize. In contrast to other breast cancer subtypes, no approved endocrine or targeted treatments exist for TNBC. Therefore, identification of the prognosis characteristisics and potential therapeutic targets of TNBC could facilitate early personalized treatment. Owing to the rapid development of various technologies, researchers are increasingly focusing on the integration of "big data" and biological sys-tems, which is referred to "omics," as means of resolving it . Here, we review the recent progress in transcriptomics and proteomics re-search on TNBC.